Tau oligomer antibodies as potential therapeutics for parkinson’s and other synucleinopathies

25 WFN15-1092 Dementia 2 Randomized, placebo-controlled, phase 1b study of anti-beta-amyloid antibody aducanumab (biib037) in prodromal ad/mild ad dementia: Interim results by patient subgroup J. Sevigny, P. Chiao, L. Williams, T. Chen, Y. Ling, J. O’Gorman, C. Hock, R. Nitsch, A. Sandrock. Clinical Development Neurodegeneration and Exp Med Clin Dev, Biogen, Cambridge, USA; Clinical Research MA Neurodegeneration and Exp Med Clin Dev, Biogen, Cambridge, USA; Drug Safety & Risk Management, Biogen, Cambridge, USA; Biostatistics Biometrics, Biogen, Cambridge, USA; Clinical Development MA MS Clin Dev Center, Biogen, Cambridge, USA; Biostatistics, Biogen, Cambridge, USA; Division of Psychiatry Research, Neurimmune Holding AG and University of Zurich, Zurich, Switzerland; Biogen, Development Sciences, Cambridge, USA